We are very encouraged to note that Oxford Pharmascience has finalised its commercial materials for both OXPzeroTM Ibuprofen and OXPzeroTM Naproxen, enabling the group to enter partnering discussions. The group has engaged consultants and advisors to support this phase of development. A key patent has also been granted in US, strengthening the group’s IP. NSAIDs represent one of the most widely used drug classes in the world, but their use is associated with GI side effects. The group's technolo ....
